Pre-Open Stock Movers 1/30: (MGEN) (TLSA) (NOW) Higher (SNDL) (BGG) (TSCO) Lower (more...)

January 30, 2020 9:28 AM EST
Get Alerts SNDL Hot Sheet
Price: $0.79 +5.33%

Overall Analyst Rating:
    NEUTRAL (Down Down)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Today's Pre-Open Stock Movers

miRagen Therapeutics, Inc. (NASDAQ: MGEN) 27.8% HIGHER; announced new efficacy and safety data from the ATLL arm of its ongoing Phase 1 clinical trial of cobomarsen, which will be presented at the 12th Annual T-Cell Lymphoma Forum in La Jolla, CA, which is taking place from January 30th to February 1st. Of note are the data from the subtype of aggressive ATLL patients who at study entry had persistent residual disease after chemotherapy or other therapy. In the trial, six patients of this subtype had an MST of 26 months with three patients still on treatment at the time of data analysis (October 17, 2019). The Company was most encouraged, however, by the observed biomarker activity showing that disease stabilization is marked by a decrease in biomarkers of tumor cells activation and proliferation, providing evidence of the biological mechanism effect of cobomarsen on disease stabilization.

Sundial Growers (NASDAQ: SNDL) 25.6% LOWER; Announces Departure of CEO and other Leadership Changes and Optimization InitiativesJan 30, 2020 08:53 AM

Briggs & Stratton (NYSE: BGG) 14.2% LOWER; reported Q2 EPS of ($0.20), $0.07 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $438 million versus the consensus estimate of $458.87 million. Briggs & Stratton sees FY2020 EPS of $0.05-$0.33, versus the consensus of $0.18. Briggs & Stratton sees FY2020 revenue of $1.83-1.97 million, versus the consensus of $1.9 million.

Albireo Pharma, Inc. (NASDAQ: ALBO) 10.2% LOWER; announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share.

Farfetch Limited (NYSE: FTCH) 9.3% HIGHER; announced that it has agreed to issue and sell, via a private placement, convertible senior notes (the Notes) in an aggregate principal amount of $250 million (the Transaction). Tencent, a global technology pioneer headquartered in Shenzhen, China, has committed to a strategic investment by agreeing to purchase $125 million of the Notes, and San Francisco-based investment firm Dragoneer has agreed to purchase the remaining $125 million of Notes. Closing of the Transaction is subject to customary conditions.

Tractor Supply (NASDAQ: TSCO) 8.7% LOWER; reported Q4 EPS of $1.21, $0.02 worse than the analyst estimate of $1.23. Revenue for the quarter came in at $2.19 billion versus the consensus estimate of $2.24 billion. Tractor Supply sees FY2020 EPS of $4.90-$5.10, versus the consensus of $5.21. Tractor Supply sees FY2020 revenue of $8.75-8.9 billion, versus the consensus of $8.96 billion.

Tesla (NASDAQ: TSLA) 8% HIGHER; reported Q4 EPS of $2.14, $0.42 better than the analyst estimate of $1.72. Revenue for the quarter came in at $7.38 billion versus the consensus estimate of $7.02 billion. Model Y production ramp started in January 2020, ahead of schedule; Record vehicle deliveries of 112,095 in Q4.

Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) 8% LOWER; intends to offer its securities in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Madrigal Pharmaceuticals (NASDAQ: MDGL) 8.2% HIGHER; Canaccord Genuity initiates coverage with a Buy rating and a price target of $198.00.

Carnival Corp. (NYSE: CCL) 8% LOWER; its unit Costa Crociere confirmed that a 54-year-old woman from Macau is in isolation on board a cruise ship at a port in Civitavecchia, Italy

Sunrun Inc. (NASDAQ: RUN) 7.7% HIGHER; will replace Darling Ingredients in the S&P SmallCap 600

Qorvo (NASDAQ: QRVO) 7.5% HIGHER; reported Q3 EPS of $1.86, $0.18 better than the analyst estimate of $1.68. Revenue for the quarter came in at $869 million versus the consensus estimate of $852.04 million. Qorvo sees Q4 2020 EPS of $1.55-$1.15. Qorvo sees Q4 2020 revenue of $800-840 million, versus the consensus of $727.8 million.

Facebook (NASDAQ: FB) 7.3% LOWER; reported Q4 EPS of $2.56, $0.03 better than the analyst estimate of $2.53. Revenue for the quarter came in at $21.08 billion versus the consensus estimate of $20.89 billion. Facebook daily active users (DAUs) – DAUs were 1.66 billion on average for December 2019, an increase of 9% year-over-year.

ServiceNow (NYSE: NOW) 7% HIGHER; reported Q4 EPS of $0.96, $0.09 better than the analyst estimate of $0.87. Revenue for the quarter came in at $951.8 million versus the consensus estimate of $941.17 million.

Cirrus Logic, Inc. (NASDAQ: CRUS) 6.7% HIGHER; reported Q3 EPS of $1.41, $0.28 better than the analyst estimate of $1.13. Revenue for the quarter came in at $374.7 million versus the consensus estimate of $346.49 million. Cirrus Logic, Inc. sees Q4 2020 revenue of $250-290 million, versus the consensus of $245.68 million.

Lam Research (NASDAQ: LRCX) 6.6% HIGHER; reported Q2 EPS of $4.01, $0.16 better than the analyst estimate of $3.85. Revenue for the quarter came in at $2.58 billion versus the consensus estimate of $2.51 billion. Lam Research sees Q3 2020 EPS of $4.55 at mid-point, versus the consensus of $4.00. Lam Research sees Q3 2020 revenue of $2.8 billion at mid-point, versus the consensus of $2.58 billion.

Aspen Technology (NASDAQ: AZPN) 6% LOWER; reported Q2 EPS of $0.66, $0.14 worse than the analyst estimate of $0.80. Revenue for the quarter came in at $124.7 million versus the consensus estimate of $135.46 million. Aspen Technology sees FY2020 EPS of $3.43-$3.84, versus the consensus of $3.79. Aspen Technology sees FY2020 revenue of $575-615 million, versus the consensus of $602.43 million.

Royal Caribbean Cruises Ltd. (NYSE: RCL) 5.9% LOWER; a rival cruise ship has passenger with possible coronoavirus

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) 5.4% LOWER; a rival cruise ship has passenger with possible coronoavirus

Illumina (NASDAQ: ILMN) 5.4% LOWER; reported Q4 EPS of $1.70, $0.12 better than the analyst estimate of $1.58. Revenue for the quarter came in at $953 million versus the consensus estimate of $942.89 million. Illumina sees FY2020 EPS of $6.80-$7.00, versus the consensus of $6.91.

DBV Technologies (Nasdaq: DBVT) 5.1% LOWER; announced its intention to launch, subject to market conditions, a global offering of new ordinary shares, which may be in the form of American Depositary Shares (ADSs), in an aggregate amount of $125.0 million.

Sherwin-Williams (NYSE: SHW) 4.8% LOWER; reported Q4 EPS of $4.27, ex-items, $0.12 worse than the analyst estimate of $4.39. Revenue for the quarter came in at $4.11 billion versus the consensus estimate of $4.2 billion. Sherwin-Williams sees FY2020 EPS of $19.91-$20.71, which may not compare to the consensus of $24.26

Applied Materials, Inc. (NASDAQ: AMAT) 4.7% HIGHER; gains on Lam Research's results.

Dolby Laboratories (NYSE: DLB) 4.6% HIGHER; reported Q1 EPS of $0.64, $0.15 better than the analyst estimate of $0.49. Revenue for the quarter came in at $291.9 million versus the consensus estimate of $285.81 million. Dolby Laboratories sees Q2 2020 EPS of $1.15-$1.21, versus the consensus of $1.16. Dolby Laboratories sees Q2 2020 revenue of $370-390 billion, versus the consensus of $379.15 billion. Dolby Laboratories sees FY2020 EPS of $3.40-$3.50, versus the consensus of $3.45. Dolby Laboratories sees FY2020 revenue of $1.3-1.35 billion, versus the consensus of $1.33 billion.

Intevac. (NASDAQ: IVAC) 4.4% HIGHER; reported Q4 EPS of $0.08, $0.12 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $31.6 million versus the consensus estimate of $34.4 million.

Align Technology (NASDAQ: ALGN) 4% LOWER; reported Q4 EPS of $1.53, $0.13 better than the analyst estimate of $1.40. Revenue for the quarter came in at $649.8 million versus the consensus estimate of $646.51 million. Sees Q1 revenue range of $615.0 million to $630.0 million and Non-GAAP diluted EPS in the range of $1.19 to $1.28, versus consensus of $1.44 on revenue of $657.3 million.

KLA Corporation (NASDAQ: KLAC) 3.1% HIGHER; gains on Lam Research's results.

Hologic (NASDAQ: HOLX) 3% LOWER; reported Q1 EPS of $0.61, in-line with the analyst estimate of $0.61. Revenue for the quarter came in at $850.5 million versus the consensus estimate of $839.82 million. Hologic sees Q2 2020 EPS of $0.61-$0.63, versus the consensus of $0.63. Hologic sees Q2 2020 revenue of $770-780 million, versus the consensus of $811.39 million. Hologic sees FY2020 EPS of $2.63-$2.67, versus the consensus of $2.61. Hologic sees FY2020 revenue of $3.238-3.268 billion, versus the consensus of $3.32 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Standard & Poor's, Tesla, Canaccord Genuity, Pre-Open Losers, Pre-Open Winners, Pre Market Movers